|
|
9M 2026
|
%
Change
|
Q3 2026
|
%
Change
|
||
|
|
$m
|
Actual
|
CER1
|
$m
|
Actual
|
CER
|
|
-
Product Sales
|
43,962
|
7
|
5
|
15,066
|
5
|
5
|
|
- Alliance Revenue
|
2,806
|
33
|
32
|
1,107
|
36
|
36
|
|
Product
Revenue
|
46,768
|
8
|
6
|
16,173
|
7
|
7
|
|
Collaboration
Revenue
|
113
|
22
|
23
|
36
|
>3x
|
>3x
|
|
Total Revenue
|
46,881
|
8
|
7
|
16,209
|
7
|
7
|
|
Reported EPS ($)
|
5.62
|
10
|
11
|
2.02
|
23
|
26
|
|
Core2 EPS ($)
|
8.00
|
14
|
14
|
2.79
|
17
|
19
|
|
Medicine
|
Trial
|
Indication
|
Event
|
|
Enhertu
|
DESTINY-Lung04
|
1L
HER2m NSCLC
|
Primary
endpoint met
|
|
Etcamah
|
SERENA-4
|
1L HR+
HER2- advanced breast cancer
|
Primary
endpoint not met
|
|
Imfinzi + tarlatamab
|
DeLLphi-305
|
1L
ES-SCLC (maintenance)
|
Primary
endpoint met
|
|
Lynparza
|
MONO-OLA1
|
1L
BRCAwt ovarian cancer
|
Dual
primary endpoints met
|
|
Tagrisso + Orpathys
|
SAFFRON
|
2L+
EGFRm, MET-overexpressed
and/or amplified NSCLC
|
Primary
endpoint met
|
|
Tagrisso + Orpathys
|
SANOVO
|
1L
EGFRm, MET-overexpressed
NSCLC
|
Primary
endpoint met
|
|
volrustomig
|
eVOLVE-Lung02
|
1L
PD-L1 <50% mNSCLC
|
Discontinued due to
futility
|
|
Tezspire
|
CROSSING
|
Eosinophilic esophagitis
|
Co-primary
endpoints met
|
|
Ultomiris
|
AWAKE
|
Delayed Graft Function
|
Discontinued due to
lack of efficacy
|
|
Medicine
|
Trial
|
Indication
|
Region
|
|
Datroway
|
TROPION-Breast02
|
1L TNBC
for patients where immunotherapy is not an option
|
EU, JP,
CN
|
|
Enhertu
|
DESTINY-Breast09
|
1L
HER2+ mBC
|
EU, JP,
CN
|
|
Enhertu
|
DESTINY-Breast05
|
High-risk
HER2+ early breast cancer (post-neoadjuvant)
|
EU,
CN
|
|
Enhertu
|
DESTINY-PanTumor02
|
HER2+
solid tumours
|
CN
|
|
Etcamah
|
SERENA-6
|
ESR1m HR+ HER2- 1L advanced breast cancer
|
US
|
|
Imfinzi
|
POTOMAC
|
NMIBC
|
JP
|
|
Breztri
|
KALOS /
LOGOS
|
Asthma
|
EU,
JP
|
|
Klygefa (gefurulimab)
|
PREVAIL
|
Generalised
myasthenia gravis
|
JP
|
|
Amlypave (anselamimab)
|
CARES
|
Kappa
light chain amyloidosis
|
JP
|
|
Ultomiris
|
I
CAN
|
IgAN
|
US
|
|
Ultomiris
|
ALXN1210-PNH-323
|
PNH
|
CN
|
|
Medicine
|
Trial
|
Indication
|
Region
|
|
Calquence
|
AMPLIFY
|
1L CLL
(fixed duration)
|
CN
|
|
Imfinzi
|
VOLGA
|
MIBC
not candidates for cisplatin
|
US, EU,
JP
|
|
Truqap
|
CAPItello-281
|
PTEN-deficient
mHSPC
|
CN
|
|
tozorakimab
|
OBERON
/ TITANIA / PROSPERO
|
COPD
|
US,
JP
|
|
Ultomiris
|
I
CAN
|
IgAN
|
CN
|
|
Ultomiris
|
ALXN1210-TMA-314
|
HSCT-TMA
(paediatric)
|
US
|
|
efzimfotase
alfa
|
MULBERRY
/ CHESTNUT / HICKORY
|
HPP
|
US, EU,
CN
|
|
For the quarter
|
Reported
|
Change
|
Core
|
Change
|
|
||
|
ended 30 September
|
$m
|
Act
|
CER
|
$m
|
Act
|
CER
|
|
|
Product
Revenue
|
16,173
|
7
|
7
|
16,173
|
7
|
7
|
*
See
Tables 3, 7, 23, 24 and 25 for further details of Product Revenue,
Product Sales and Alliance Revenue
|
|
Collaboration
Revenue
|
36
|
>3x
|
>3x
|
36
|
>3x
|
>3x
|
*
See
Tables 4 and 26 for further details of Collaboration
Revenue
|
|
Total
Revenue
|
16,209
|
7
|
7
|
16,209
|
7
|
7
|
*
See
Tables 5 and 6 for Total Revenue by Therapy Area and by
region
|
|
Gross
Margin (%)
|
82
|
-
|
+1pp
|
82
|
-
|
+1pp
|
+ Positive product
mix effects
– Pricing headwinds,
including those driven by loss of exclusivity and VBP in
China
*
Variations in Gross
Margin can be expected between periods due to various factors,
including fluctuations in foreign exchange rates, product
seasonality and
Collaboration Revenue
|
|
R&D
expense
|
3,894
|
6
|
7
|
3,645
|
3
|
3
|
*
Core
R&D: 22% of Total Revenue (23% for 9M 2026)
+ Increasing number
of trials, and patients in those trials
+ Investments in
transformative technologies
+ Addition of
R&D projects from business development
Positive data
readouts for high value pipeline opportunities that have ungated
large late-stage trials
*
Variations in the
year-on-year change in R&D expenses can be expected between
periods due to the phasing of trial starts and
completions
|
|
SG&A
expense
|
5,108
|
-
|
-
|
3,909
|
2
|
2
|
*
Core
SG&A: 24% of Total Revenue (25% for 9M 2026)
+ Investment to
support ongoing and future launches
*
Variations in the
year-on-year change in SG&A expenses can be expected between
periods due to the phasing of product launches and other
programmes
|
|
Other
operating income and expense4
|
277
|
>3x
|
>3x
|
277
|
>2x
|
>2x
|
+ Various partner
milestones and royalties
+ Disposal of
Zoryve interest
|
|
Operating
profit
|
4,387
|
22
|
26
|
5,855
|
17
|
20
|
+ See commentary
above on Gross Margin, R&D, SG&A
|
|
Operating
Margin (%)
|
27
|
+3pp
|
+4pp
|
36
|
+3pp
|
+4pp
|
and Other operating
income and expense
|
|
Net
finance expense
|
410
|
17
|
22
|
371
|
22
|
27
|
+ Lower interest
income on short-term deposits and higher interest expense on
short-term borrowings
+ Higher discount
unwind on lease liabilities, principally due to the new strategic
R&D centre in Massachusetts, US
– Reported Net
finance expense benefitted from a lower discount unwind on
contingent consideration liabilities
|
|
Tax
rate (%)
|
21
|
-1pp
|
-1pp
|
21
|
-
|
-1pp
|
*
Variations in the
tax rate can be expected between periods
|
|
EPS
($)
|
2.02
|
23
|
26
|
2.79
|
17
|
19
|
+ See commentary
above
|
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Tagrisso
|
5,862
|
13
|
10
|
8
|
2,087
|
13
|
12
|
12
|
|
Imfinzi
|
5,538
|
12
|
28
|
27
|
1,990
|
12
|
24
|
26
|
|
Calquence
|
3,009
|
6
|
18
|
16
|
1,065
|
7
|
16
|
16
|
|
Lynparza
|
2,421
|
5
|
1
|
(2)
|
811
|
5
|
(3)
|
(3)
|
|
Enhertu
|
2,688
|
6
|
36
|
33
|
969
|
6
|
36
|
35
|
|
Zoladex
|
967
|
2
|
9
|
5
|
336
|
2
|
13
|
10
|
|
Truqap
|
641
|
1
|
30
|
29
|
210
|
1
|
9
|
9
|
|
Imjudo
|
263
|
1
|
4
|
4
|
103
|
1
|
23
|
25
|
|
Datroway
|
176
|
-
|
>4x
|
>4x
|
78
|
-
|
>3x
|
>3x
|
|
Etcamah
|
10
|
-
|
n/m
|
n/m
|
7
|
-
|
n/m
|
n/m
|
|
Other
Oncology
|
313
|
1
|
(3)
|
(4)
|
109
|
1
|
2
|
3
|
|
Oncology PR
|
21,888
|
47
|
18
|
16
|
7,765
|
48
|
17
|
17
|
|
Farxiga
|
5,603
|
12
|
(12)
|
(15)
|
1,605
|
10
|
(25)
|
(25)
|
|
Crestor
|
1,018
|
2
|
8
|
5
|
332
|
2
|
9
|
6
|
|
Lokelma
|
638
|
1
|
23
|
23
|
219
|
1
|
16
|
17
|
|
Seloken
|
519
|
1
|
11
|
6
|
182
|
1
|
14
|
9
|
|
Brilinta
|
261
|
1
|
(61)
|
(62)
|
75
|
-
|
(48)
|
(50)
|
|
Wainua
|
189
|
-
|
33
|
33
|
68
|
-
|
16
|
17
|
|
roxadustat
|
78
|
-
|
(66)
|
(68)
|
21
|
-
|
(73)
|
(74)
|
|
Baxfendy
|
12
|
-
|
n/m
|
n/m
|
9
|
-
|
n/m
|
n/m
|
|
Other
CVRM
|
298
|
1
|
(29)
|
(30)
|
92
|
1
|
(36)
|
(34)
|
|
Cardiovascular, Renal & Metabolism PR
|
8,616
|
18
|
(11)
|
(15)
|
2,603
|
16
|
(19)
|
(20)
|
|
Symbicort
|
2,084
|
4
|
(4)
|
(7)
|
666
|
4
|
(10)
|
(11)
|
|
Fasenra
|
1,655
|
4
|
14
|
13
|
602
|
4
|
13
|
14
|
|
Breztri
|
1,073
|
2
|
18
|
16
|
374
|
2
|
16
|
14
|
|
Tezspire
|
1,123
|
2
|
46
|
44
|
429
|
3
|
50
|
51
|
|
Saphnelo
|
615
|
1
|
27
|
27
|
235
|
1
|
31
|
32
|
|
Pulmicort
|
378
|
1
|
6
|
2
|
109
|
1
|
18
|
16
|
|
Airsupra
|
129
|
-
|
12
|
13
|
42
|
-
|
(7)
|
(4)
|
|
Other
R&I
|
211
|
-
|
(9)
|
(11)
|
61
|
-
|
3
|
1
|
|
Respiratory & Immunology PR
|
7,268
|
16
|
12
|
10
|
2,518
|
16
|
11
|
11
|
|
Beyfortus
|
427
|
1
|
(10)
|
(10)
|
233
|
1
|
(1)
|
(2)
|
|
FluMist
|
172
|
-
|
30
|
29
|
146
|
1
|
20
|
20
|
|
Other
ID
|
136
|
-
|
(38)
|
(41)
|
44
|
-
|
(24)
|
(25)
|
|
Infectious Disease PR
|
735
|
2
|
(11)
|
(12)
|
423
|
3
|
2
|
1
|
|
Ultomiris
|
4,016
|
9
|
16
|
16
|
1,432
|
9
|
17
|
19
|
|
Soliris
|
1,076
|
2
|
(25)
|
(26)
|
298
|
2
|
(35)
|
(35)
|
|
Strensiq
|
1,641
|
4
|
38
|
37
|
588
|
4
|
33
|
34
|
|
Koselugo
|
585
|
1
|
17
|
15
|
238
|
1
|
6
|
9
|
|
Other
Rare Disease
|
226
|
-
|
28
|
25
|
77
|
-
|
20
|
24
|
|
Rare Disease PR
|
7,544
|
16
|
12
|
11
|
2,633
|
16
|
9
|
10
|
|
Other
Medicines PR
|
717
|
1
|
(5)
|
(6)
|
231
|
1
|
(3)
|
(3)
|
|
Product Revenue
|
46,768
|
100
|
8
|
6
|
16,173
|
100
|
7
|
7
|
|
|
|
|
|
|
|
|
|
|
|
Alliance Revenue included above:
|
|
|
|
|
|
|
|
|
|
Enhertu
|
1,670
|
4
|
29
|
27
|
612
|
4
|
34
|
34
|
|
Tezspire
|
614
|
1
|
36
|
35
|
242
|
1
|
44
|
44
|
|
Beyfortus
|
279
|
1
|
11
|
11
|
156
|
1
|
11
|
10
|
|
Datroway
|
164
|
-
|
>4x
|
>4x
|
71
|
-
|
>2x
|
>2x
|
|
Other
royalty revenue
|
76
|
-
|
8
|
8
|
25
|
-
|
8
|
4
|
|
Other
Alliance Revenue
|
3
|
-
|
(16)
|
(16)
|
1
|
-
|
3
|
3
|
|
Alliance Revenue
|
2,806
|
6
|
33
|
32
|
1,107
|
7
|
36
|
36
|
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
|
Actual
|
CER
|
$m
|
|
Actual
|
CER
|
|
Farxiga: sales milestones
|
80
|
|
(2)
|
(1)
|
36
|
|
>6x
|
>7x
|
|
Crestor: sales milestones
|
32
|
|
n/m
|
n/m
|
-
|
|
n/m
|
n/m
|
|
Others
|
1
|
|
(89)
|
(87)
|
-
|
|
n/m
|
n/m
|
|
Collaboration Revenue
|
113
|
|
22
|
23
|
36
|
|
>3x
|
>3x
|
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
21,889
|
47
|
18
|
16
|
7,765
|
48
|
17
|
17
|
|
- Cardiovascular, Renal & Metabolism
|
8,728
|
19
|
(11)
|
(14)
|
2,639
|
16
|
(18)
|
(18)
|
|
- Respiratory & Immunology
|
7,268
|
16
|
12
|
10
|
2,518
|
16
|
11
|
11
|
|
- Infectious Disease
|
735
|
2
|
(11)
|
(12)
|
423
|
3
|
2
|
1
|
|
BioPharmaceuticals
|
16,731
|
36
|
(2)
|
(5)
|
5,580
|
34
|
(5)
|
(6)
|
|
Rare
Disease
|
7,544
|
16
|
12
|
11
|
2,633
|
16
|
9
|
10
|
|
Other
Medicines
|
717
|
2
|
(6)
|
(8)
|
231
|
1
|
(5)
|
(5)
|
|
Total Revenue
|
46,881
|
100
|
8
|
7
|
16,209
|
100
|
7
|
7
|
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
US
|
19,789
|
42
|
7
|
7
|
6,899
|
43
|
5
|
5
|
|
- Emerging Markets ex. China
|
7,085
|
15
|
11
|
8
|
2,276
|
14
|
4
|
4
|
|
- China
|
5,430
|
12
|
3
|
(3)
|
1,920
|
12
|
9
|
3
|
|
Emerging
Markets
|
12,515
|
27
|
7
|
3
|
4,196
|
26
|
6
|
4
|
|
Europe
|
10,528
|
22
|
15
|
10
|
3,706
|
23
|
11
|
12
|
|
Established
RoW
|
4,049
|
9
|
4
|
7
|
1,408
|
9
|
4
|
11
|
|
Total Revenue
|
46,881
|
100
|
8
|
7
|
16,209
|
100
|
7
|
7
|
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
US
|
19,788
|
42
|
7
|
7
|
6,899
|
43
|
5
|
5
|
|
- Emerging Markets ex. China
|
7,085
|
15
|
11
|
8
|
2,276
|
14
|
4
|
4
|
|
- China
|
5,430
|
12
|
3
|
(3)
|
1,920
|
12
|
9
|
3
|
|
Emerging
Markets
|
12,515
|
27
|
7
|
3
|
4,196
|
26
|
6
|
4
|
|
Europe
|
10,528
|
23
|
15
|
10
|
3,706
|
23
|
11
|
12
|
|
Established
RoW
|
3,937
|
8
|
3
|
7
|
1,372
|
8
|
3
|
9
|
|
Total Product Revenue
|
46,768
|
100
|
8
|
6
|
16,173
|
100
|
7
|
7
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Strong
demand growth across indications and key regions, positioned as
backbone across all stages of EGFRm NSCLC. Leading combination in 1L
NSCLC (FLAURA2)
|
||
|
US
|
2,467
|
11
|
11
|
|
*
Robust
underlying demand
|
|
|
Emerging
Markets
|
1,656
|
10
|
6
|
|
*
More
competitive environment in China in a slowing EGFRm TKI market
|
|
|
Europe
|
1,169
|
13
|
8
|
|
|
|
|
Established
RoW
|
570
|
(3)
|
1
|
|
*
Recent
competitor entrant
|
|
|
Total
|
5,862
|
10
|
8
|
|
|
|
|
9M 2026
$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Strong
demand growth across all regions from existing indications and new
launches
|
||
|
US
|
3,128
|
26
|
26
|
|
*
Demand
growth led by new GI and GU launches (MATTERHORN,
NIAGARA)
|
|
|
Emerging
Markets
|
627
|
35
|
33
|
|
*
Strong
growth in GI (HIMALAYA, TOPAZ) including new launches
(MATTERHORN)
|
|
|
Europe
|
1,210
|
38
|
31
|
|
*
Early
momentum for new lung (ADRIATIC), GI (MATTERHORN) and GU (NIAGARA)
launches
|
|
|
Established
RoW
|
573
|
17
|
23
|
|
*
Demand
growth from new launches across GYN (DUO-E), GU (NIAGARA) and lung
(ADRIATIC, AEGEAN)
|
|
|
Total
|
5,538
|
28
|
27
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Sustained BTKi
leadership in front-line CLL with launch momentum across finite use
for 1L CLL (AMPLIFY) and 1L MCL (ECHO)
|
||
|
US
|
1,982
|
16
|
16
|
|
*
Strong
demand growth from ongoing leadership in front-line CLL BTKi
market
|
|
|
Emerging
Markets
|
214
|
31
|
25
|
|
|
|
|
Europe
|
690
|
21
|
16
|
|
*
Rapid
AMPLIFY adoption across key markets and further expansion in 1L
MCL
|
|
|
Established
RoW
|
123
|
6
|
6
|
|
|
|
|
Total
|
3,009
|
18
|
16
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Global
leadership in mature first-generation PARPi market, volume growth
offset by pricing in some markets
|
||
|
US
|
1,012
|
(4)
|
(4)
|
|
*
Demand
growth offset by gross to net adjustments
|
|
|
Emerging
Markets
|
507
|
4
|
(1)
|
|
*
Affected by generic
competition in China and VBP implementation
|
|
|
Europe
|
710
|
6
|
1
|
|
*
Stable
volumes
|
|
|
Established
RoW
|
192
|
-
|
3
|
|
|
|
|
Total
|
2,421
|
1
|
(2)
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Standard-of-care in
HER2-positive (DESTINY-Breast03) and HER2-low (DESTINY-Breast04)
metastatic breast cancer, early uptake in other
cancers
|
||
|
US
|
1,122
|
35
|
35
|
|
*
Ongoing
adoption in 1L HER2-positive breast cancer (DESTINY-Breast09) and
early uptake following early breast cancer launches
(DESTINY-Breast05, DESTINY-Breast11)
|
|
|
Emerging
Markets
|
849
|
44
|
41
|
|
*
Broader
adoption and improved access across regions
|
|
|
Europe
|
596
|
22
|
15
|
|
*
Further
demand growth in chemotherapy naïve HER2-low breast
cancer
|
|
|
Established
RoW
|
121
|
91
|
90
|
|
|
|
|
Total
|
2,688
|
36
|
33
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Zoladex
|
968
|
9
|
5
|
|
*
Growth
across Emerging Markets, partly offset by divestment of rights in
Japan in May 2026
|
|
|
Truqap
|
641
|
30
|
29
|
|
*
Achieved peak share
in US in second-line biomarker-altered metastatic breast cancer; Q3
2026 affected by US destocking following bottle to blister
transition
|
|
|
Imjudo
|
263
|
4
|
4
|
|
*
Continued GI
(HIMALAYA) growth ex-US and China launch in Q3 2026, offset by
lower demand in some markets
|
|
|
Datroway
|
176
|
>4x
|
>4x
|
|
*
Continued uptake in
breast cancer with early adoption in 1L TNBC (TROPION-Breast02),
and EGFRm later-line lung
cancer
*
Combined global
sales by AstraZeneca and Daiichi Sankyo: $413m (9M 2025:
$115m)
|
|
|
Etcamah
|
10
|
n/m
|
n/m
|
|
*
Initial
uptake following US launch (SERENA-6)
|
|
|
Other
Oncology
|
313
|
(3)
|
(4)
|
|
*
Generic
erosion across markets
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Growth
impacted by US LoE and China VBP
|
||
|
US
|
795
|
(36)
|
(36)
|
|
*
Multiple generics
launched in Q2 2026
|
|
|
Emerging
Markets
|
2,200
|
(16)
|
(21)
|
|
*
Affected by generic
competition, VBP implementation in China in Q1 2026 and
unfavourable tender timing in some Emerging Markets
|
|
|
Europe
|
2,385
|
11
|
6
|
|
*
Demand
growth partly offset by generic entry in the UK in Q3
2025
|
|
|
Established
RoW
|
303
|
(27)
|
(25)
|
|
*
Generic
T2D entry in Japan in Q4 2025. Milestone receipts in Q1 and Q3
2026
|
|
|
Total
|
5,683
|
(12)
|
(15)
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Crestor
|
1,050
|
11
|
8
|
|
*
Growth
driven by Emerging Markets
|
|
|
Lokelma
|
638
|
23
|
23
|
|
*
Growth
in all major regions
|
|
|
Seloken
|
519
|
11
|
6
|
|
*
Growth
driven by Emerging Markets
|
|
|
Brilinta
|
261
|
(61)
|
(62)
|
|
*
Decline
driven by generic entry in the US and Europe in Q2
2025
|
|
|
Wainua
|
189
|
33
|
33
|
|
*
Demand
growth in ATTR-PN and geographic expansion
|
|
|
roxadustat
|
78
|
(66)
|
(68)
|
|
*
Affected by generic
competition in China and VBP implementation in Q1 2026
|
|
|
Baxfendy
|
12
|
n/m
|
n/m
|
|
*
US
launch in hypertension in Q2 2026
|
|
|
Other
CVRM
|
298
|
(29)
|
(30)
|
|
*
Generic
erosion
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Market
leader in ICS/LABA class with increasing generic
competition
|
||
|
US
|
772
|
(15)
|
(15)
|
|
*
Demand
for brand offset by price pressure; launch of additional generic in
market
|
|
|
Emerging
Markets
|
653
|
5
|
1
|
|
|
|
|
Europe
|
425
|
5
|
(1)
|
|
|
|
|
Established
RoW
|
234
|
(5)
|
(7)
|
|
|
|
|
Total
|
2,084
|
(4)
|
(7)
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Continued severe
eosinophilic asthma market share leadership in IL-5 class, further
fuelled by accelerated EGPA and HES indication
launches
|
||
|
US
|
949
|
7
|
7
|
|
*
Strong
demand with IL-5 class leadership
|
|
|
Emerging
Markets
|
149
|
85
|
78
|
|
*
Strong
China uptake post Q1 2026 NRDL listing with growth in other key
markets
|
|
|
Europe
|
389
|
11
|
5
|
|
*
Increased
leadership in severe eosinophilic asthma partially offset by
pricing
|
|
|
Established
RoW
|
168
|
26
|
30
|
|
*
Strong
growth supported by EGPA in Japan
|
|
|
Total
|
1,655
|
14
|
13
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Fastest
growing medicine within the expanding FDC triple class
(ICS/LABA/LAMA)
|
||
|
US
|
479
|
4
|
4
|
|
*
Share
growth in COPD and asthma launch offset by gross-to-net
adjustments
|
|
|
Emerging
Markets
|
329
|
38
|
31
|
|
*
Market
share leadership within FDC triple class in China
|
|
|
Europe
|
183
|
34
|
28
|
|
*
Sustained growth
from market share gains
|
|
|
Established
RoW
|
82
|
19
|
21
|
|
|
|
|
Total
|
1,073
|
18
|
16
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Sustained demand
growth in severe asthma with launch momentum across multiple
markets
|
||
|
US
|
614
|
36
|
35
|
|
*
Continued strong
demand growth in severe asthma and launch of CRSwNP
|
|
|
Emerging
Markets
|
64
|
>2x
|
>2x
|
|
*
Strong
continued uptake
|
|
|
Europe
|
322
|
56
|
49
|
|
*
Continued
new-to-brand leadership across multiple markets and market
growth
|
|
|
Established
RoW
|
123
|
43
|
48
|
|
|
|
|
Total
|
1,123
|
46
|
44
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Saphnelo
|
615
|
27
|
27
|
|
*
Strong
demand growth fuelled by s.c. launches
|
|
|
Pulmicort
|
378
|
6
|
2
|
|
*
Emerging Market
growth offset by pressure in Europe and Established
RoW
|
|
|
Airsupra
|
129
|
12
|
13
|
|
*
US
demand volume growth partially offset by pricing
pressures
|
|
|
Other R&I
|
211
|
(9)
|
(11)
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Beyfortus
|
427
|
(10)
|
(10)
|
|
*
Partner’s
adjustment of inventory levels
|
|
|
FluMist
|
172
|
30
|
29
|
|
|
|
|
Other
ID
|
136
|
(38)
|
(41)
|
|
*
Other
includes Synagis, which
declined due to competition from Beyfortus
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Growth
due to patient demand, both naïve to C5 medicines and
conversion from Soliris
across all indications (gMG, NMOSD, aHUS and PNH)
|
||
|
US
|
2,190
|
12
|
12
|
|
*
Demand
growth across indications, including within the competitive gMG and
PNH landscapes
|
|
|
Emerging
Markets
|
306
|
73
|
73
|
|
*
Expansion into new
markets and growth in patient demand
|
|
|
Europe
|
915
|
19
|
14
|
|
*
Demand
growth following launches; competition in gMG and PNH
|
|
|
Established
RoW
|
605
|
11
|
16
|
|
*
Continued
conversion and strong patient demand
|
|
|
Total
|
4,016
|
16
|
16
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Decline
driven by conversion of patients to Ultomiris across all indications
|
||
|
US
|
595
|
(30)
|
(30)
|
|
*
Affected by
biosimilar pressure
|
|
|
Emerging
Markets
|
311
|
(5)
|
(7)
|
|
|
|
|
Europe
|
89
|
(44)
|
(47)
|
|
*
Affected by
biosimilar pressure in PNH and aHUS
|
|
|
Established
RoW
|
81
|
(24)
|
(23)
|
|
|
|
|
Total
|
1,076
|
(25)
|
(26)
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Growth
driven by continued HPP patient demand
|
||
|
US
|
1,332
|
40
|
40
|
|
|
|
|
Emerging
Markets
|
111
|
81
|
67
|
|
*
Continued launches
in new markets
|
|
|
Europe
|
104
|
17
|
12
|
|
*
Demand
growth and improved access following new launches
|
|
|
Established
RoW
|
94
|
11
|
17
|
|
|
|
|
Total
|
1,641
|
38
|
37
|
|
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Koselugo
|
585
|
17
|
15
|
|
*
Continued patient
demand, strong uptake following launch of adult indication. Q3 2026
benefitted from tender order timing in Emerging
Markets
|
|
|
Other
Rare Disease
|
226
|
28
|
25
|
|
*
Other
Rare Disease medicines include Kanuma, and Beyonttra (JP only)
|
|
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Other
Medicines
|
717
|
(6)
|
(8)
|
|
*
Generic
erosion
|
|
|
Approval
EU
|
TROPION-Breast02
July
2026
|
*
As monotherapy for
the 1st-line treatment of adult patients with unresectable or
metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor
therapy.
|
|
Approval
JP
|
TROPION-Breast02
September
2026
New disclosure
|
*
1st-line treatment
of unresectable or metastatic TNBC not candidates for PD-1/PD-L1
inhibitor therapy.
|
|
Approval
CN
|
TROPION-Breast02
October
2026
New disclosure
|
*
For
patients with unresectable or metastatic TNBC not candidates for
PD-1/PD-L1 inhibitor therapy.
|
|
Phase III readout and data presentation
WCLC
|
DESTINY-Lung04
August/September
2026
|
*
Positive results
from the DESTINY-Lung04 Phase III trial showed Enhertu reduced the risk of disease
progression or death by 37% versus pembrolizumab plus chemotherapy
(HR 0.63; 95% CI 0.50-0.79; p<0.0001) as 1st-line treatment of
patients with unresectable, locally advanced or metastatic
HER2-mutant non-squamous NSCLC. Median PFS was 14.3 months with
Enhertu compared to 8.3
months for pembrolizumab plus chemotherapy.
|
|
Approval
CN
|
DESTINY-Breast09
August
2026
New disclosure
|
*
In
combination with pertuzumab for the 1st-line treatment of adult
patients with unresectable or metastatic HER2-positive breast
cancer.
|
|
Approval
EU
|
DESTINY-Breast09
September
2026
|
*
In
combination with pertuzumab for the 1st-line treatment of adult
patients with unresectable or metastatic HER2-positive breast
cancer.
|
|
Approval
JP
|
DESTINY-Breast09
September
2026
New disclosure
|
*
In combination with
pertuzumab for the 1st-line treatment of adult patients with
unresectable or metastatic HER2-positive breast
cancer.
|
|
Approval
CN
|
DESTINY-Breast05
October
2026
New disclosure
|
*
Adjuvant treatment
of adult patients with HER2-positive early breast cancer who have
residual invasive disease after neoadjuvant taxane and
trastuzumab-based treatment.
|
|
Approval
CN
|
DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02 and
DESTINY-PanTumor03
October
2026
New disclosure
|
*
Unresectable or
metastatic solid tumours with HER2 expression (IHC 3+) who have
received prior treatment or have no satisfactory alternative
treatment options.
|
|
Approval
EU
|
DESTINY-Breast05
October
2026
|
*
As
monotherapy for the adjuvant treatment of adult patients with
resected HER2-positive breast cancer who have residual invasive
disease after neoadjuvant taxane-based and HER2-targeted
treatment.
|
|
Approval
US
|
SERENA-6
September
2026
|
*
In
combination with a CDK4/6 inhibitor (abemaciclib, palbociclib or
ribociclib) for HR-positive, HER2-negative, locally advanced or
metastatic breast cancer upon detection of ESR1 mutation during aromatase
inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorised
test.
|
|
Phase III readout
|
SERENA-4
September
2026
|
*
The
SERENA-4 Phase III trial of Etcamah in combination with palbociclib
did not meet the primary endpoint of PFS, however a numerical
improvement was observed in the upfront 1st-line treatment of
patients with ER-positive, HER2-negative advanced breast cancer who
have not received any systemic treatment for advanced disease. The
trial evaluated the Etcamah
combination versus treatment with an aromatase inhibitor
(anastrozole) in combination with palbociclib.
|
|
Approval
JP
|
POTOMAC
August
2026
New disclosure
|
*
In
combination with Bacillus Calmette-Guérin for the treatment of
adult patients with BCG-naïve, high-risk non-muscle-invasive
bladder cancer.
|
|
Phase III readout and data presentation
ESMO
|
DeLLphi-305
September/October
2026
|
*
Positive results
from the DeLLphi-305 Phase III trial showed Imfinzi plus tarlatamab reduced the
risk of death by 58% versus Imfinzi alone (HR 0.42; 95% CI
0.32-0.54; p<0.001) as 1st-line maintenance treatment for
patients with ES-SCLC who had not progressed following standard
induction treatment with Imfinzi plus platinum-etoposide
chemotherapy. Median OS was 21.1 months with Imfinzi plus tarlatamab compared to
12.7 months for Imfinzi
alone.
|
|
CHMP opinion
EU
|
Label update
September
2026
New disclosure
|
*
Recommended update
to the Imfinzi label
reducing the infusion time from 60 to 30 minutes.
|
|
Priority Review
US
|
VOLGA
September
2026
|
*
Perioperative
treatment with Imfinzi in
combination with neoadjuvant enfortumab vedotin for patients with
MIBC who are ineligible for or have declined cisplatin-based
chemotherapy.
|
|
Data presentation
ESMO
|
VOLGA
October
2026
|
*
Positive results
from a planned interim analysis of the VOLGA Phase III trial showed
perioperative Imfinzi plus
neoadjuvant enfortumab vedotin reduced the risk of disease
progression, recurrence, not undergoing surgery or death by 49%
versus radical cystectomy with or without approved adjuvant
treatment (EFS HR 0.51; 95% CI 0.38-0.67; p<0.0001) in patients
with MIBC who were ineligible for or had refused cisplatin-based
chemotherapy. Median EFS was not reached with the Imfinzi regimen compared to 12.1 months
for the comparator arm. For the key secondary endpoint of OS, the
Imfinzi regimen reduced the
risk of death by 42% (HR 0.58; 95% CI 0.40-0.83;
p=0.0027).
|
|
Phase III readout
|
MONO-OLA1
Q3
2026
New disclosure
|
*
Positive high-level
results from the MONO-OLA1 Phase III trial showed that both primary
endpoints were met, with Lynparza demonstrating statistically
significant improvements in PFS versus placebo in both the BRCAwt
HRD-positive and BRCAwt populations when used as 1st-line
maintenance treatment for patients with newly diagnosed high grade
serous or endometrioid ovarian cancer. The safety profile of
Lynparza observed in
MONO-OLA1 was generally consistent with its known profile.
AstraZeneca does not intend to progress with regulatory filings in
US, Europe, China or Japan given the increasing trend towards PARP
inhibitors being approved and used primarily in the BRCAm and
HRD-positive settings in 1L ovarian cancer, a population where
Lynparza +/- bevacizumab,
is already the established standard of care.
|
|
Phase III readout and data presentation
ESMO
|
SAFFRON
August/October
2026
|
*
Positive results
from the SAFFRON Phase III trial showed Tagrisso plus Orpathys reduced the risk of disease
progression or death by 45% versus doublet platinum-based
chemotherapy (HR 0.55; 95% CI 0.42-0.72; p<0.001) in patients
with EGFRm locally advanced
or metastatic NSCLC with high levels of MET overexpression or
amplification who had progressed on prior treatment with
Tagrisso. Median PFS was
7.6 months with Tagrisso
plus Orpathys compared to
5.4 months for chemotherapy. For the key secondary endpoint of OS,
Tagrisso plus Orpathys reduced the risk of death by
32% (HR 0.68; 95% CI 0.50-0.91; p=0.010), extending median OS by
4.9 months (17.8 versus 12.9 months).
|
|
Phase III readout and data presentation
ESMO
|
SANOVO
September/October
2026
|
*
Positive results
from the SANOVO China-only Phase III trial showed Tagrisso plus Orpathys reduced the risk of disease
progression or death by 44% versus Tagrisso alone in the
intention-to-treat population (HR 0.56; 95% CI 0.43-0.74;
p<0.0001) and by 55% in the high MET (IHC 3+) population (HR
0.45; 95% CI 0.31-0.66; p<0.0001) in treatment-naïve
patients with EGFRm locally
advanced or metastatic NSCLC and MET overexpression. Median PFS was
24.9 months with Tagrisso
plus Orpathys compared to
13.8 months for Tagrisso
alone in the intention-to-treat population. For the secondary
endpoint of OS in the intention-to-treat population, Tagrisso plus Orpathys showed a very encouraging
clinical benefit versus Tagrisso alone (HR 0.48; 95% CI
0.33-0.68), with median OS of 44.5 months compared to 34.9
months.
|
|
Data presentation
WCLC
|
ADAURA
September
2026
|
*
Updated
exploratory results from the ADAURA Phase III trial showed
Tagrisso demonstrated a
sustained, clinically meaningful OS benefit at eight years compared
to placebo in the adjuvant treatment of patients with early-stage
(IB, II and IIIA) EGFRm
NSCLC after complete tumour resection, reducing the risk of death
by 47% in the primary population (Stage II-IIIA) (HR 0.53; 95% CI
0.38-0.75) and by 48% in the overall trial population (HR 0.52; 95%
CI 0.39-0.71).
|
|
Regulatory update
EU
|
CAPItello-281
October
2026
New disclosure
|
*
Withdrawal of the
Type II variation application for Truqap in combination with abiraterone
for the treatment of PTEN-deficient metastatic hormone-sensitive
prostate cancer, based on the CAPItello-281 Phase III
trial.
|
|
Data presentation
ESMO
|
CLARITY-Gastric01
October
2026
|
*
Positive results
from a planned interim analysis of the CLARITY-Gastric01 Phase III
trial showed sonesitatug vedotin reduced the risk of death by 53%
versus investigator’s choice of therapy (HR 0.47; 95% CI
0.36-0.62; p<0.001) in patients with 3rd- and later-line
CLDN18.2-positive advanced gastric, GEJ or oesophageal
adenocarcinoma. Median OS was 10.0 months with sonesitatug vedotin
compared to 5.0 months for investigator’s choice of therapy.
In the overall 2nd- and later-line trial population, sonesitatug
vedotin reduced the risk of death by 42% (HR 0.58; 95% CI
0.47-0.73; p<0.001); the other dual primary endpoint of PFS in
this population did not reach statistical
significance.
|
|
Phase III trial update
|
eVOLVE-Lung02
August
2026
|
*
The
eVOLVE-Lung02 Phase III trial of volrustomig in combination with
chemotherapy versus pembrolizumab and chemotherapy as 1st-line
treatment for patients with metastatic NSCLC whose tumours express
PD-L1 <50% has been discontinued, following an IDMC
recommendation that the combination was unlikely to meet either of
the dual primary endpoints of PFS or OS in the primary analysis
population of patients with PD-L1 negative tumours (<1%). The
other Phase III volrustomig trials continue as
planned.
|
|
Data presentationESC
|
CARDIO-TTRansform
August 2026
|
*
Wainua in
patients with ATTR-CM did not meet the primary efficacy endpoint of
the composite outcome of CV mortality and recurrent CV clinical
events up to 140 weeks compared with placebo (rate ratio (RR) 0.89,
95% CI, 0.73-1.09, P=0.277). In a prespecified analysis,
Wainua reduced the risk of
CV death and recurrent CV events by 29% vs. placebo in
patients not receiving a stabiliser at baseline (RR
0.71, 95% CI, 0.54-0.93).
|
|
Approval
EU
(Trixeo)
|
KALOS / LOGOS
September 2026
|
*
Maintenance
treatment of asthma in patients 12 years of age and older who are
not adequately controlled by a combination of a medium dose inhaled
corticosteroid and long-acting b₂-agonist.
|
|
Approval
JP
(Breztri)
|
KALOS / LOGOS
September 2026
New disclosure
|
*
For
bronchial asthma (when a combination of an inhaled corticosteroid,
a long-acting inhaled anticholinergic agent and a long-acting
inhaled b₂-agonist is necessary). The intended use population
includes both adults and children aged 12 years or
above.
|
|
Approval
US (Breztri)
|
NGP programme
October 2026
New disclosure
|
*
Breztri, already licensed for the
treatment of COPD in adults and asthma in patients 12 years of age
and older, has received approval in the US for the updated
formulation containing AstraZeneca’s next-generation
propellant with near-zero global warming potential.
|
|
Phase III readout and data presentation
UEGW
|
CROSSINGSeptember / October
2026
|
*
Positive results
from the CROSSING Phase III trial demonstrated that treatment with
Tezspire achieved
histologic remission for 64.8% (210mg dose) and 68.9% (420mg dose)
of patients at week 24, compared to 3.5% of patients on placebo
(p<0.001). Tezspire also
reduced the frequency and severity of dysphagia symptoms by 18.8
points (210mg dose; p=0.049) and 22.0 points (420mg dose,
p<0.001) from baseline vs. 14.7 on placebo, as measured by the
Dysphagia Symptom Questionnaire (DSQ) score, a patient-reported
outcome measure. Efficacy was sustained in both doses through week
52, as measured in key secondary endpoints.
|
|
Data presentation
ERS
|
OBERON / TITANIA
September 2026
|
*
Positive results
from the OBERON and TITANIA Phase III trials demonstrated that
tozorakimab, administered once every four weeks, demonstrated a
reduction in moderate and severe COPD exacerbations in the primary
population of former smokers by 29% (OBERON) and 34% (TITANIA), and
in the overall population of current and former smokers by 30%
(OBERON) and 29% (TITANIA) compared with placebo while on inhaled
standard of care. In addition, based on a pooled analysis of OBERON
and TITANIA, patients on tozorakimab with a baseline blood
eosinophil count of less than 150 cells/uL achieved a 23% reduction
in moderate and severe exacerbations; patients at or above 150
achieved a 34% reduction; and patients at or above 300 achieved a
43% reduction.
|
|
Priority Review
US
|
OBERON / TITANIA / PROSPERO
August 2026
|
*
Add-on
maintenance treatment for adult patients with COPD.
|
|
Data presentationCHEST
|
PROSPEROOctober
2026
|
*
In the
PROSPERO long-term extension trial of OBERON and TITANIA,
tozorakimab demonstrated a numerical, but not statistically
significant, reduction in severe exacerbations (a different primary
endpoint than OBERON and TITANIA) in the primary endpoint
population of former smokers (21%; 0.26 vs 0.33 annualised rates;
RR 0.79 (95% CI 0.61,1.01) p=0.0587). There was a nominally
significant reduction in severe exacerbations in the overall
population of former and current smokers (27%; 0.26 vs 0.36
annualised rates; RR 0.73 (95% CI 0.58, 0.91) p=0.0046). Consistent
with the primary endpoint in the OBERON and TITANIA trials,
PROSPERO, in a secondary endpoint, showed continued tozorakimab
treatment maintained the reduction in moderate and severe COPD
exacerbations in former smokers and the overall population at 104
weeks. The safety and tolerability profile of tozorakimab through
104 weeks in PROSPERO was consistent with the profile observed in
the OBERON and TITANIA trials.
|
|
Approval
JP
|
CARES
September 2026
|
*
For
systemic light chain (AL) amyloidosis (only in patients with
predominantly kappa immunoglobulin light chain).
|
|
Data presentation
ASBMR
|
HICKORY
October 2026
|
*
In the
overall population, at week 25, efzimfotase alfa achieved a least
squares (LS) mean difference of 17.05 metres (p=0.1675) change from
baseline in the primary endpoint of 6MWT, compared to placebo. The
lack of statistical significance was largely due to
better-than-expected results observed in the adult-onset HPP
placebo group.
*
In a
combination of prespecified subgroups of adolescents and adults
with paediatric-onset HPP, efzimfotase alfa demonstrated nominally
significant and clinically meaningful benefits in the primary
endpoint of 6MWT, achieving an LS mean difference of 35.6 metres
(nominal p=0.0386) vs placebo at week 25, as well as the key
secondary endpoints of 30s-STS (LS mean difference vs placebo: 1.3;
nominal p=0.0384) and BPI-SF Pain Severity (LS mean difference vs
placebo: -1.0; nominal p=0.0260).
|
|
Priority Review
US
|
HICKORY/MULBERRY/CHESTNUT
September 2026
|
Patients with
hypophosphatasia aged ≥2 years.
|
|
Approval
JP
|
PREVAIL
September 2026
New disclosure
|
*
For
generalised myasthenia gravis (only for patients who are not
adequately responsive to steroids or nonsteroidal
immunosuppressants).
|
|
CHMP opinion
EU
|
PREVAIL
September
2026
|
*
Recommended as an
add-on to standard therapy for the treatment of generalised
myasthenia gravis (gMG) in adults who are anti-acetylcholine
receptor (AChR) antibody-positive.
|
|
Approval
CN
|
ALXN1210-PNH-323
August
2026
New disclosure
|
*
For the
treatment of adult and paediatric patients one month of age and
older with paroxysmal nocturnal haemoglobinuria.
|
|
Phase III trial update
|
AWAKE
October
2026
New disclosure
|
*
AWAKE
Phase III clinical trial evaluating Ultomiris in adult kidney transplant
recipients who are at risk of delayed graft function has been
discontinued, following an IDMC recommendation that Ultomiris was unlikely to meet the
trial’s primary endpoint of time to freedom from dialysis
through 90 days post-transplant versus placebo. The safety profile
observed in this trial was consistent with the known profile of
Ultomiris, with no new
safety concerns identified.
|
|
Approval
US
|
I CAN
October
2026
|
*
For the
reduction of proteinuria in adults with primary immunoglobulin A
nephropathy who are at risk for disease progression.
|
|
Priority Review
US
|
ALXN1210-TMA-314
ALX-TMA-502
September
2026
New disclosure
|
*
Paediatric patients
with haematopoietic stem cell transplant-associated thrombotic
microangiopathy.
|
|
|
9M 2026
|
9M 2025
|
%
Change
|
Q3 2026
|
Q3 2025
|
%
Change
|
||
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
- Product Sales
|
43,962
|
41,035
|
7
|
5
|
15,066
|
14,365
|
5
|
5
|
|
- Alliance Revenue
|
2,806
|
2,108
|
33
|
32
|
1,107
|
815
|
36
|
36
|
|
Product
Revenue
|
46,768
|
43,143
|
8
|
6
|
16,173
|
15,180
|
7
|
7
|
|
Collaboration
Revenue
|
113
|
93
|
22
|
23
|
36
|
11
|
>3x
|
>3x
|
|
Total Revenue
|
46,881
|
43,236
|
8
|
7
|
16,209
|
15,191
|
7
|
7
|
|
Cost of
sales
|
(8,147)
|
(7,515)
|
8
|
3
|
(2,946)
|
(2,801)
|
5
|
2
|
|
Gross profit
|
38,734
|
35,721
|
8
|
7
|
13,263
|
12,390
|
7
|
8
|
|
Distribution
expense
|
(437)
|
(426)
|
3
|
(1)
|
(151)
|
(148)
|
3
|
2
|
|
R&D
expense
|
(11,439)
|
(10,370)
|
10
|
9
|
(3,894)
|
(3,663)
|
6
|
7
|
|
SG&A
expense
|
(15,679)
|
(14,441)
|
9
|
7
|
(5,108)
|
(5,085)
|
-
|
-
|
|
Other
operating income & expense
|
618
|
281
|
>2x
|
>2x
|
277
|
89
|
>3x
|
>3x
|
|
Operating profit
|
11,797
|
10,765
|
10
|
10
|
4,387
|
3,583
|
22
|
26
|
|
Net
finance expense
|
(1,085)
|
(985)
|
10
|
9
|
(410)
|
(349)
|
17
|
22
|
|
Joint
ventures and associates
|
(41)
|
(7)
|
>5x
|
>5x
|
(19)
|
10
|
n/m
|
n/m
|
|
Profit before tax
|
10,671
|
9,773
|
9
|
10
|
3,958
|
3,244
|
22
|
25
|
|
Taxation
|
(1,966)
|
(1,869)
|
5
|
6
|
(842)
|
(709)
|
19
|
22
|
|
Tax rate
|
18%
|
19%
|
|
|
21%
|
22%
|
|
|
|
Profit after tax
|
8,705
|
7,904
|
10
|
11
|
3,116
|
2,535
|
23
|
26
|
|
Earnings per share
|
$5.62
|
$5.10
|
10
|
11
|
$2.02
|
$1.64
|
23
|
26
|
|
|
9M 2026
|
9M 2025
|
%
Change
|
Q3 2026
|
Q3 2025
|
%
Change
|
||
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit before tax
|
10,671
|
9,773
|
9
|
10
|
3,958
|
3,244
|
22
|
25
|
|
Net
finance expense
|
1,085
|
985
|
10
|
9
|
410
|
349
|
17
|
22
|
|
Joint
ventures and associates
|
41
|
7
|
>5x
|
>5x
|
19
|
(10)
|
n/m
|
n/m
|
|
Depreciation,
amortisation and impairment
|
4,900
|
4,222
|
16
|
15
|
1,605
|
1,549
|
4
|
4
|
|
EBITDA
|
16,697
|
14,987
|
11
|
11
|
5,992
|
5,132
|
17
|
19
|
|
For the nine
months ended 30
September
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Other
|
Core
|
% Change
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross profit
|
38,734
|
13
|
19
|
3
|
38,769
|
9
|
7
|
|
- Gross Margin
|
83%
|
|
|
|
83%
|
-
|
+1pp
|
|
Distribution
expense
|
(437)
|
1
|
-
|
-
|
(436)
|
2
|
(1)
|
|
R&D
expense
|
(11,439)
|
157
|
511
|
3
|
(10,768)
|
7
|
5
|
|
- R&D % of Total Revenue
|
24%
|
|
|
|
23%
|
-
|
-
|
|
SG&A
expense
|
(15,679)
|
258
|
3,194
|
409
|
(11,818)
|
7
|
4
|
|
- SG&A % of Total Revenue
|
33%
|
|
|
|
25%
|
-
|
+1pp
|
|
Total
operating expense
|
(27,555)
|
416
|
3,705
|
412
|
(23,022)
|
7
|
5
|
|
Other
operating income & expense
|
618
|
(1)
|
-
|
1
|
618
|
>2x
|
>2x
|
|
Operating profit
|
11,797
|
428
|
3,724
|
416
|
16,365
|
14
|
14
|
|
- Operating Margin
|
25%
|
|
|
|
35%
|
+2pp
|
+2pp
|
|
Net
finance expense
|
(1,085)
|
-
|
-
|
93
|
(992)
|
21
|
20
|
|
Taxation
|
(1,966)
|
(103)
|
(738)
|
(122)
|
(2,929)
|
11
|
12
|
|
EPS
|
$5.62
|
$0.21
|
$1.93
|
$0.24
|
$8.00
|
14
|
14
|
|
For the quarter ended 30 September
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Other
|
Core
|
% Change
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross profit
|
13,263
|
16
|
3
|
-
|
13,282
|
7
|
8
|
|
- Gross Margin
|
82%
|
|
|
|
82%
|
-
|
+1pp
|
|
Distribution
expense
|
(151)
|
1
|
-
|
-
|
(150)
|
2
|
1
|
|
R&D
expense
|
(3,894)
|
100
|
147
|
2
|
(3,645)
|
3
|
3
|
|
- R&D % of Total Revenue
|
24%
|
|
|
|
22%
|
+1pp
|
+1pp
|
|
SG&A
expense
|
(5,108)
|
152
|
1,038
|
9
|
(3,909)
|
2
|
2
|
|
- SG&A % of Total Revenue
|
32%
|
|
|
|
24%
|
+1pp
|
+1pp
|
|
Total
operating expense
|
(9,153)
|
253
|
1,185
|
11
|
(7,704)
|
2
|
2
|
|
Other
operating income & expense
|
277
|
(1)
|
-
|
1
|
277
|
>2x
|
>2x
|
|
Operating profit
|
4,387
|
268
|
1,188
|
12
|
5,855
|
17
|
20
|
|
- Operating Margin
|
27%
|
|
|
|
36%
|
+3pp
|
+4pp
|
|
Net
finance expense
|
(410)
|
-
|
-
|
39
|
(371)
|
22
|
27
|
|
Taxation
|
(842)
|
(63)
|
(224)
|
(11)
|
(1,140)
|
14
|
16
|
|
EPS
|
$2.02
|
$0.13
|
$0.62
|
$0.02
|
$2.79
|
17
|
19
|
|
For the nine
months ended 30
September
|
9M 2026
$m
|
9M 2025
$m
|
Change$m
|
|
Reported
Operating profit
|
11,797
|
10,765
|
1,032
|
|
Depreciation,
amortisation and impairment
|
4,900
|
4,222
|
678
|
|
Movement
in working capital and short-term provisions
|
(1,730)
|
64
|
(1,794)
|
|
Gains
on disposal of intangible assets
|
(156)
|
(118)
|
(38)
|
|
Fair
value movements on contingent consideration arising from business
combinations
|
(15)
|
(29)
|
14
|
|
Non-cash
and other movements
|
(125)
|
591
|
(716)
|
|
Interest
paid
|
(1,147)
|
(1,069)
|
(78)
|
|
Taxation
paid
|
(2,634)
|
(2,193)
|
(441)
|
|
Net cash inflow from operating activities
|
10,890
|
12,233
|
(1,343)
|
|
Net cash outflow from investing activities
|
(6,589)
|
(5,362)
|
(1,227)
|
|
Net cash outflow from financing activities
|
(2,066)
|
(4,262)
|
2,196
|
|
Net increase in cash and cash equivalents in the
period
|
2,235
|
2,609
|
(374)
|
|
|
At 30 Sep 2026
$m
|
At 31 Dec 2025
$m
|
At 30 Sep 2025
$m
|
|
Cash
and cash equivalents
|
7,936
|
5,711
|
8,143
|
|
Other
investments
|
230
|
30
|
39
|
|
Cash and investments
|
8,166
|
5,741
|
8,182
|
|
Overdrafts
and short-term borrowings
|
(473)
|
(644)
|
(622)
|
|
Commercial
paper
|
(1,619)
|
-
|
(1,091)
|
|
Lease
liabilities
|
(2,777)
|
(1,803)
|
(1,758)
|
|
Current
instalments of loans
|
(2,857)
|
(2,460)
|
(4,461)
|
|
Non-current
instalments of loans
|
(26,465)
|
(24,715)
|
(24,700)
|
|
Interest-bearing loans and borrowings (Gross debt)
|
(34,191)
|
(29,622)
|
(32,632)
|
|
Net
derivatives
|
192
|
507
|
485
|
|
Net debt
|
(25,833)
|
(23,374)
|
(23,965)
|
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Total
Revenue
|
-
|
-
|
|
Gross
profit
|
-
|
-
|
|
Operating
loss
|
(5)
|
-
|
|
Loss
for the period
|
(832)
|
(957)
|
|
Transactions
with subsidiaries that are not issuers or guarantors
|
6,740
|
6,509
|
|
|
At 30 Sep 2026
$m
|
At 30 Sep 2025
$m
|
|
Current
assets
|
129
|
13
|
|
Non-current
assets
|
11
|
141
|
|
Current
liabilities
|
(4,704)
|
(5,976)
|
|
Non-current
liabilities
|
(26,568)
|
(24,704)
|
|
Amounts
due from subsidiaries that are not issuers or
guarantors
|
25,450
|
21,519
|
|
Amounts
due to subsidiaries that are not issuers or guarantors
|
-
|
-
|
|
Currency
|
Primary Relevance
|
Exchange rate vs USD (average rate in period)
|
Annual impact of 5% strengthening vs USD1
($m)
|
|||||
|
|
|
FY 20252
|
YTD 20263
|
Change
(%)
|
Sep 20264
|
Change
(%)
|
Total Revenue
|
Core Operating Profit
|
|
EUR
|
Total
Revenue
|
0.88
|
0.86
|
3
|
0.87
|
2
|
499
|
234
|
|
CNY
|
Total
Revenue
|
7.19
|
6.82
|
5
|
6.71
|
7
|
329
|
178
|
|
JPY
|
Total
Revenue
|
149.64
|
158.51
|
(6)
|
156.40
|
(5)
|
179
|
120
|
|
GBP
|
Operating
expense
|
0.76
|
0.74
|
2
|
0.75
|
2
|
50
|
(180)
|
|
SEK
|
Operating
expense
|
9.81
|
9.38
|
4
|
9.75
|
1
|
9
|
(71)
|
|
Other
|
|
|
|
|
|
|
615
|
339
|
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
- Product Sales
|
43,962
|
41,035
|
|
- Alliance Revenue
|
2,806
|
2,108
|
|
Product
Revenue
|
46,768
|
43,143
|
|
Collaboration
Revenue
|
113
|
93
|
|
Total Revenue
|
46,881
|
43,236
|
|
Cost of
sales
|
(8,147)
|
(7,515)
|
|
Gross profit
|
38,734
|
35,721
|
|
Distribution
expense
|
(437)
|
(426)
|
|
Research
and development expense
|
(11,439)
|
(10,370)
|
|
Selling,
general and administrative expense
|
(15,679)
|
(14,441)
|
|
Other
operating income and expense
|
618
|
281
|
|
Operating profit
|
11,797
|
10,765
|
|
Finance
income
|
217
|
225
|
|
Finance
expense
|
(1,302)
|
(1,210)
|
|
Share
of after tax losses in associates and joint ventures
|
(41)
|
(7)
|
|
Profit before tax
|
10,671
|
9,773
|
|
Taxation
|
(1,966)
|
(1,869)
|
|
Profit for the period
|
8,705
|
7,904
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
Items that will not be reclassified to profit and
loss:
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
268
|
116
|
|
Net
gains/(losses) on equity investments measured at fair value through
Other comprehensive income
|
529
|
(21)
|
|
Tax
expense on items that will not be reclassified to profit or
loss
|
(77)
|
(13)
|
|
|
720
|
82
|
|
Items that may be reclassified subsequently to profit and
loss:
|
|
|
|
Foreign
exchange arising on consolidation
|
(862)
|
2,266
|
|
Foreign
exchange arising on designated liabilities in net investment
hedges
|
47
|
15
|
|
Fair
value movements on cash flow hedges
|
(12)
|
256
|
|
Fair
value movements on cash flow hedges transferred to profit and
loss
|
114
|
(318)
|
|
Fair
value movements on derivatives designated in net investment
hedges
|
(17)
|
(7)
|
|
(Costs)/gains
of hedging
|
(70)
|
8
|
|
Tax
expense on items that may be reclassified subsequently to profit
and loss
|
(14)
|
(50)
|
|
|
(814)
|
2,170
|
|
Other comprehensive (expense)/income for the period, net of
tax
|
(94)
|
2,252
|
|
|
|
|
|
Total comprehensive income for the period
|
8,611
|
10,156
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
Owners
of the Parent
|
8,704
|
7,899
|
|
Non-controlling
interests
|
1
|
5
|
|
|
8,705
|
7,904
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
Owners
of the Parent
|
8,612
|
10,149
|
|
Non-controlling
interests
|
(1)
|
7
|
|
|
8,611
|
10,156
|
|
Earnings per share
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
$5.62
|
$5.10
|
|
Diluted
earnings per $0.25 Ordinary Share
|
$5.58
|
$5.06
|
|
Weighted
average number of Ordinary Shares in issue (millions)
|
1,550
|
1,550
|
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
1,561
|
1,561
|
|
For the quarter ended 30 September
|
2026
$m
|
2025
$m
|
|
- Product Sales
|
15,066
|
14,365
|
|
- Alliance Revenue
|
1,107
|
815
|
|
Product
Revenue
|
16,173
|
15,180
|
|
Collaboration
Revenue
|
36
|
11
|
|
Total Revenue
|
16,209
|
15,191
|
|
Cost of
sales
|
(2,946)
|
(2,801)
|
|
Gross profit
|
13,263
|
12,390
|
|
Distribution
expense
|
(151)
|
(148)
|
|
Research
and development expense
|
(3,894)
|
(3,663)
|
|
Selling,
general and administrative expense
|
(5,108)
|
(5,085)
|
|
Other
operating income and expense
|
277
|
89
|
|
Operating profit
|
4,387
|
3,583
|
|
Finance
income
|
67
|
85
|
|
Finance
expense
|
(477)
|
(434)
|
|
Share
of after tax (losses)/gains in associates and joint
ventures
|
(19)
|
10
|
|
Profit before tax
|
3,958
|
3,244
|
|
Taxation
|
(842)
|
(709)
|
|
Profit for the period
|
3,116
|
2,535
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
Items that will not be reclassified to profit and
loss:
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
35
|
146
|
|
Net
gains on equity investments measured at fair value through Other
comprehensive income
|
64
|
104
|
|
Tax
expense on items that will not be reclassified to profit or
loss
|
(26)
|
(10)
|
|
|
73
|
240
|
|
Items that may be reclassified subsequently to profit and
loss:
|
|
|
|
Foreign
exchange arising on consolidation
|
(163)
|
(198)
|
|
Foreign
exchange arising on designated liabilities in net investment
hedges
|
4
|
5
|
|
Fair
value movements on cash flow hedges
|
69
|
(17)
|
|
Fair
value movements on cash flow hedges transferred to profit and
loss
|
18
|
(3)
|
|
Fair
value movements on derivatives designated in net investment
hedges
|
(21)
|
13
|
|
Costs
of hedging
|
(70)
|
(2)
|
|
Tax
(expense)/income on items that may be reclassified subsequently to
profit and loss
|
(21)
|
2
|
|
|
(184)
|
(200)
|
|
Other comprehensive (expense)/income for the period, net of
tax
|
(111)
|
40
|
|
|
|
|
|
Total comprehensive income for the period
|
3,005
|
2,575
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
Owners
of the Parent
|
3,117
|
2,533
|
|
Non-controlling
interests
|
(1)
|
2
|
|
|
3,116
|
2,535
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
Owners
of the Parent
|
3,006
|
2,575
|
|
Non-controlling
interests
|
(1)
|
-
|
|
|
3,005
|
2,575
|
|
Earnings per share
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
$2.02
|
$1.64
|
|
Diluted
earnings per $0.25 Ordinary Share
|
$2.00
|
$1.62
|
|
Weighted
average number of Ordinary Shares in issue (millions)
|
1,551
|
1,551
|
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
1,560
|
1,561
|
|
|
|
At 30
Sep 2026
|
At 31
Dec 2025
|
At 30
Sep 2025
|
|
Assets
|
|
$m
|
$m
|
$m
|
|
Non-current assets
|
|
|
|
|
|
Property,
plant and equipment
|
|
14,064
|
12,962
|
12,083
|
|
Right-of-use
assets
|
|
2,714
|
1,741
|
1,700
|
|
Goodwill
|
|
21,157
|
21,242
|
21,219
|
|
Intangible
assets
|
|
38,146
|
37,846
|
38,191
|
|
Investments
in associates and joint ventures
|
|
268
|
302
|
296
|
|
Other
investments
|
|
2,676
|
2,223
|
1,990
|
|
Derivative
financial instruments
|
|
306
|
498
|
502
|
|
Other
receivables
|
|
1,426
|
1,327
|
1,159
|
|
Income
tax receivable
|
|
1,062
|
1,391
|
1,247
|
|
Deferred
tax assets
|
|
6,655
|
5,819
|
6,129
|
|
|
|
88,474
|
85,351
|
84,516
|
|
Current assets
|
|
|
|
|
|
Inventories
|
|
6,883
|
6,557
|
6,593
|
|
Trade
and other receivables
|
|
14,736
|
15,177
|
14,338
|
|
Other
investments
|
|
230
|
30
|
39
|
|
Derivative
financial instruments
|
|
20
|
90
|
12
|
|
Income
tax receivable
|
|
1,643
|
1,158
|
815
|
|
Cash
and cash equivalents
|
|
7,936
|
5,711
|
8,143
|
|
|
|
31,448
|
28,723
|
29,940
|
|
Total assets
|
|
119,922
|
114,074
|
114,456
|
|
Liabilities
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(4,949)
|
(3,104)
|
(6,174)
|
|
Lease
liabilities
|
|
(445)
|
(382)
|
(379)
|
|
Trade
and other payables
|
|
(23,572)
|
(25,280)
|
(25,028)
|
|
Derivative
financial instruments
|
|
(26)
|
(81)
|
(29)
|
|
Provisions
|
|
(654)
|
(686)
|
(1,176)
|
|
Income
tax payable
|
|
(1,621)
|
(1,084)
|
(1,268)
|
|
|
|
(31,267)
|
(30,617)
|
(34,054)
|
|
Non-current liabilities
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(26,465)
|
(24,715)
|
(24,700)
|
|
Lease
liabilities
|
|
(2,332)
|
(1,421)
|
(1,379)
|
|
Derivative
financial instruments
|
|
(108)
|
-
|
-
|
|
Deferred
tax liabilities
|
|
(3,617)
|
(3,500)
|
(3,604)
|
|
Retirement
benefit obligations
|
|
(780)
|
(1,105)
|
(1,271)
|
|
Provisions
|
|
(988)
|
(918)
|
(929)
|
|
Income
tax payable
|
|
(293)
|
(700)
|
(535)
|
|
Other
payables
|
|
(2,258)
|
(2,379)
|
(2,013)
|
|
|
|
(36,841)
|
(34,738)
|
(34,431)
|
|
Total liabilities
|
|
(68,108)
|
(65,355)
|
(68,485)
|
|
Net assets
|
|
51,814
|
48,719
|
45,971
|
|
Equity
|
|
|
|
|
|
Share
capital
|
|
388
|
388
|
388
|
|
Share
premium account
|
|
35,286
|
35,266
|
35,243
|
|
Other
reserves
|
|
1,985
|
2,041
|
2,044
|
|
Retained
earnings
|
|
14,069
|
10,972
|
8,213
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
51,728
|
48,667
|
45,888
|
|
Non-controlling
interests
|
|
86
|
52
|
83
|
|
Total equity
|
|
51,814
|
48,719
|
45,971
|
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the Parent
|
Non-controlling interests
|
Total equity
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January 2025
|
388
|
35,226
|
2,012
|
3,160
|
40,786
|
85
|
40,871
|
|
Profit
for the period
|
-
|
-
|
-
|
7,899
|
7,899
|
5
|
7,904
|
|
Other
comprehensive (expense)/income
|
-
|
-
|
(61)
|
2,311
|
2,250
|
2
|
2,252
|
|
Transfer
to Other reserves
|
-
|
-
|
48
|
(48)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(4,846)
|
(4,846)
|
-
|
(4,846)
|
|
Dividends
paid to non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
(2)
|
(2)
|
|
Issue
of Ordinary Shares
|
-
|
17
|
-
|
-
|
17
|
-
|
17
|
|
Changes
in non-controlling interests
|
-
|
-
|
-
|
8
|
8
|
(7)
|
1
|
|
Movement
in shares held by Employee Benefit Trusts
|
-
|
-
|
45
|
-
|
45
|
-
|
45
|
|
Share-based
payments charge for the period
|
-
|
-
|
-
|
529
|
529
|
-
|
529
|
|
Settlement
of share plan awards
|
-
|
-
|
-
|
(800)
|
(800)
|
-
|
(800)
|
|
Net movement
|
-
|
17
|
32
|
5,053
|
5,102
|
(2)
|
5,100
|
|
At 30 September 2025
|
388
|
35,243
|
2,044
|
8,213
|
45,888
|
83
|
45,971
|
|
|
|
|
|
|
|
|
|
|
At 1 January 2026
|
388
|
35,266
|
2,041
|
10,972
|
48,667
|
52
|
48,719
|
|
Profit
for the period
|
-
|
-
|
-
|
8,704
|
8,704
|
1
|
8,705
|
|
Other
comprehensive income/(expense)
|
-
|
-
|
27
|
(119)
|
(92)
|
(2)
|
(94)
|
|
Transfer
to Other reserves
|
-
|
-
|
10
|
(10)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(5,002)
|
(5,002)
|
-
|
(5,002)
|
|
Dividends
paid to non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
(2)
|
(2)
|
|
Issue
of Ordinary Shares
|
-
|
20
|
-
|
-
|
20
|
-
|
20
|
|
Changes
in non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
37
|
37
|
|
Movement
in shares held by Employee Benefit Trusts
|
-
|
-
|
(93)
|
-
|
(93)
|
-
|
(93)
|
|
Share-based
payments charge for the period
|
-
|
-
|
-
|
574
|
574
|
-
|
574
|
|
Settlement
of share plan awards
|
-
|
-
|
-
|
(1,050)
|
(1,050)
|
-
|
(1,050)
|
|
Net movement
|
-
|
20
|
(56)
|
3,097
|
3,061
|
34
|
3,095
|
|
At 30 September 2026
|
388
|
35,286
|
1,985
|
14,069
|
51,728
|
86
|
51,814
|
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Cash flows from operating activities
|
|
|
|
Profit
before tax
|
10,671
|
9,773
|
|
Finance
income and expense
|
1,085
|
985
|
|
Share
of after tax losses of associates and joint ventures
|
41
|
7
|
|
Depreciation,
amortisation and impairment
|
4,900
|
4,222
|
|
Movement
in working capital and short-term provisions
|
(1,730)
|
64
|
|
Gains
on disposal of intangible assets
|
(156)
|
(118)
|
|
Fair
value movements on contingent consideration arising from business
combinations
|
(15)
|
(29)
|
|
Non-cash
and other movements
|
(125)
|
591
|
|
Cash generated from operations
|
14,671
|
15,495
|
|
Interest
paid
|
(1,147)
|
(1,069)
|
|
Tax
paid
|
(2,634)
|
(2,193)
|
|
Net cash inflow from operating activities
|
10,890
|
12,233
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
Acquisition
of businesses, net of cash acquired1
|
(600)
|
(60)
|
|
Payment
of contingent consideration from business combinations
|
(290)
|
(897)
|
|
Purchase
of property, plant and equipment
|
(1,986)
|
(1,774)
|
|
Disposal
of property, plant and equipment
|
13
|
10
|
|
Purchase
of intangible assets
|
(3,862)
|
(2,844)
|
|
Disposal
of intangible assets
|
180
|
96
|
|
Purchase
of non-current asset investments
|
(18)
|
(218)
|
|
Disposal
of non-current asset investments
|
3
|
-
|
|
Movement
in short-term investments, fixed deposits and other investing
instruments
|
(196)
|
122
|
|
Payments
to associates and joint ventures
|
(14)
|
(10)
|
|
Interest
received
|
181
|
213
|
|
Net cash outflow from investing activities
|
(6,589)
|
(5,362)
|
|
Net cash inflow before financing activities
|
4,301
|
6,871
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
Proceeds
from issue of share capital
|
20
|
17
|
|
Own
shares purchased by Employee Benefit Trusts
|
(763)
|
(508)
|
|
Payments
to acquire non-controlling interests
|
-
|
(14)
|
|
Issue
of loans and borrowings
|
4,972
|
9
|
|
Repayment
of loans and borrowings
|
(2,456)
|
(20)
|
|
Dividends
paid
|
(4,955)
|
(4,968)
|
|
Hedge
contracts relating to dividend payments
|
(52)
|
113
|
|
Repayment
of obligations under leases
|
(282)
|
(273)
|
|
Movement
in short-term borrowings
|
1,450
|
1,382
|
|
Net cash outflow from financing activities
|
(2,066)
|
(4,262)
|
|
|
|
|
|
Net increase in Cash and cash equivalents in the
period
|
2,235
|
2,609
|
|
Cash
and cash equivalents at the beginning of the period
|
5,698
|
5,429
|
|
Exchange
rate effects
|
(16)
|
42
|
|
Cash and cash equivalents at the end of the period
|
7,917
|
8,080
|
|
|
|
|
|
Cash and cash equivalents consist of:
|
|
|
|
Cash
and cash equivalents
|
7,936
|
8,143
|
|
Overdrafts
|
(19)
|
(63)
|
|
|
7,917
|
8,080
|
|
|
At 1 Jan 2026
|
Cash flow
|
Non-cash
and other
|
Exchange
movements
|
At 30 Sep 2026
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current
instalments of loans
|
(24,715)
|
(4,952)
|
2,979
|
223
|
(26,465)
|
|
Non-current
instalments of leases
|
(1,421)
|
-
|
(930)
|
19
|
(2,332)
|
|
Total long-term debt
|
(26,136)
|
(4,952)
|
2,049
|
242
|
(28,797)
|
|
Current
instalments of loans
|
(2,460)
|
2,453
|
(2,872)
|
22
|
(2,857)
|
|
Current
instalments of leases
|
(382)
|
368
|
(437)
|
6
|
(445)
|
|
Commercial
paper
|
-
|
(1,619)
|
-
|
-
|
(1,619)
|
|
Collateral
received from derivative counterparties
|
(473)
|
155
|
-
|
-
|
(318)
|
|
Other
short-term borrowings excluding overdrafts
|
(158)
|
14
|
-
|
8
|
(136)
|
|
Overdrafts
|
(13)
|
(6)
|
-
|
-
|
(19)
|
|
Total current debt
|
(3,486)
|
1,365
|
(3,309)
|
36
|
(5,394)
|
|
Gross borrowings
|
(29,622)
|
(3,587)
|
(1,260)
|
278
|
(34,191)
|
|
Net
derivative financial instruments
|
507
|
457
|
(772)
|
-
|
192
|
|
Net borrowings
|
(29,115)
|
(3,130)
|
(2,032)
|
278
|
(33,999)
|
|
Cash
and cash equivalents
|
5,711
|
2,241
|
-
|
(16)
|
7,936
|
|
Other
investments - current
|
30
|
200
|
-
|
-
|
230
|
|
Cash and investments
|
5,741
|
2,441
|
-
|
(16)
|
8,166
|
|
Net debt
|
(23,374)
|
(689)
|
(2,032)
|
262
|
(25,833)
|
|
Farxiga
patent proceedings,
US
|
*
In May
2021, AstraZeneca proceeded to trial against ANDA filer Zydus
Pharmaceuticals (USA) Inc. (Zydus) in the US District Court for the
District of Delaware (District Court). In October 2021, the
District Court issued a decision finding the asserted claims of
AstraZeneca’s patent as valid and infringed by Zydus’s
ANDA product. In August 2022, Zydus appealed the District Court
decision. Zydus’s appeal has been dismissed.
*
In
December 2023, AstraZeneca initiated ANDA litigation against Sun
Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries,
Inc. in the District Court. In September 2026, the District Court
dismissed the matter.
*
This
matter is concluded.
|
|
Koselugo
patent proceedings,
US
|
*
In
September 2026, AstraZeneca received a paragraph IV notice from
Hetero USA, Inc. challenging patents relating to Koselugo.
*
AstraZeneca intends
to file responsive ANDA litigation.
*
This
matter remains at an early stage.
|
|
Lynparza
patent proceedings,
Canada
|
* In
July 2025, AstraZeneca was served with a Notice of Allegation from
Cipla Ltd (Cipla) challenging a patent relating to Lynparza. AstraZeneca commenced an
action in response in August 2025. In August 2026, AstraZeneca
entered into a settlement agreement with Cipla resolving all Canada
patent litigation with Cipla relating to Lynparza.
*
In
August 2025, AstraZeneca was served with a Notice of Allegation
from Natco Pharma (Canada) Inc. (Natco) challenging a patent
relating to Lynparza.
AstraZeneca commenced an action in response in October 2025. In
September 2026, AstraZeneca entered into a settlement agreement
with Natco resolving all Canada patent litigation with Natco
relating to Lynparza.
* In
November 2025, AstraZeneca was served with a Notice of Allegation
from Zydus Lifesciences Limited challenging a patent relating to
Lynparza. AstraZeneca
commenced an action in response in December 2025. A summary trial
related to infringement is scheduled for January 2027 and a trial
on other matters has not yet been scheduled.
|
|
Lynparza
patent proceedings,
US
|
*
AstraZeneca
received a Paragraph IV notice relating to Lynparza patents from Natco Pharma
Limited (Natco) in December 2022, Sandoz Inc. (Sandoz) in December
2023, Cipla USA, Inc. and Cipla Limited (collectively, Cipla) in
May 2024, and Zydus Pharmaceuticals (USA) Inc. (Zydus) in November
2024.
*
In
response to these Paragraph IV notices, AstraZeneca, MSD
International Business GmbH, and the University of Sheffield
initiated ANDA litigations against Natco, Sandoz, Cipla, and Zydus
in the US District Court for the District of New Jersey. In the
complaints, AstraZeneca alleged that the defendants’ generic
versions of Lynparza, if
approved and marketed, would infringe AstraZeneca’s
patents.
*
In
April 2026, AstraZeneca entered into a settlement agreement with
Sandoz resolving all US patent litigation with Sandoz relating to
Lynparza.
*
Trial
has been scheduled to commence with the remaining defendants in
January 2027.
*
In June
2026, AstraZeneca received Paragraph IV notices from Cipla relating
to Lynparza dosage
strengths not at issue in the previous litigation. In July 2026,
AstraZeneca commenced responsive litigation. That matter remains at
an early stage.
|
|
Tagrisso
patent proceedings,
Russia
|
* In
August 2023, AstraZeneca filed lawsuits in the Arbitration Court of
the Moscow region (Court) against the Russian Ministry of Health
(MOH) and Axelpharm LLC (Axelpharm) for improper use of AstraZeneca
information in the authorisation of a generic version
of Tagrisso. The suit
against the MOH was dismissed in July 2024, after two appeals. The
case against Axelpharm was dismissed in September 2024, and a
subsequent appeal by AstraZeneca was also dismissed.
*
In
November 2023, Axelpharm sought a compulsory licence under a patent
related to Tagrisso;
the action remains pending. The Axelpharm patent on which the
compulsory licensing action was based was held invalid by the
Russian Patent and Trademark Office (PTO) in August 2024, following
a challenge by AstraZeneca. The PTO’s decision was upheld in
June 2025, following an appeal by Axelpharm. At a further appeal
hearing in November 2025, the Intellectual Property Court Presidium
reversed earlier decisions and held Axelpharm’s patent valid.
The Supreme Court rejected appeals by AstraZeneca and the PTO
against this decision in February 2026. AstraZeneca filed a
new invalidity claim against Axelpharm’s patent in May
2026.
*
In July
2024, AstraZeneca filed a patent infringement claim against
Axelpharm in relation to a generic version of Tagrisso. The action was stayed by the
Court pending resolution of the compulsory licensing action. In
July 2026, AstraZeneca filed a patent infringement claim against
OncoTarget LLC (OncoTarget) in relation to the manufacture of a
generic version of Tagrisso
and a further claim against Pharmproekt Limited Liability Company
based on their participation in tenders relating to a generic
version of Tagrisso.
*
In
August 2024, after AstraZeneca filed a complaint, the Federal
Anti-Monopoly Service of Russia (FAS) initiated a case against
Axelpharm and OncoTarget. In November 2024, the FAS found Axelpharm
(but not OncoTarget) to have committed unfair competition. In June
2025, the finding against Axelpharm was reversed on appeal. In
December 2025, on appeal by AstraZeneca, the appellate decision was
affirmed. AstraZeneca filed a further appeal, and in April 2026,
the Intellectual Property Court restored the FAS’s finding of
unfair competition and prohibited Axelpharm from selling the
generic drug.
|
|
Farxiga
Privacy Litigation,
US
Considered to be a contingent liability
|
*
In
September 2026, a putative class action was filed in California
State Court alleging that tracking technologies used on the
Farxiga website collected
and disclosed certain visitor information in violation of the
privacy laws of California and other states.
*
This
matter remains at an early stage.
|
|
Syntimmune Milestone Litigation, US
Considered to be a contingent liability
|
*
As
previously disclosed, since 2020, AstraZeneca has been defending a
lawsuit filed in connection with AstraZeneca's acquisition of
Syntimmune, Inc. (Syntimmune) by the stockholders’
representative for Syntimmune in Delaware State Court (Court) that
alleged, among other things, breaches of the 2018 merger agreement
(Merger Agreement).
*
The
stockholders’ representative alleged that AstraZeneca failed
to meet its obligations under the Merger Agreement to use
commercially reasonable efforts to achieve the milestones.
AstraZeneca also filed a claim for breach of the representations in
the Merger Agreement.
*
A trial
was held in July 2023. The Court issued partial decisions in
September 2024, June 2025, and May 2026, concluding that the first
milestone was achieved, that AstraZeneca had breached its
contractual obligation to use commercially reasonable efforts to
achieve the milestones, and that sellers breached a material
representation in the Merger Agreement regarding manufacturing of
drug substance and product supply.
*
In October 2026,
the Court entered final judgment on its earlier decisions issuing a
$392 million judgment, plus post judgment interest, against
AstraZeneca.
*
AstraZeneca intends
to appeal.
|
|
Respiratory Biologics False Claims
Act Litigation, US
Considered to be a contingent liability
|
*
In
October 2026, AstraZeneca was served with an unsealed civil lawsuit
brought by qui tam relators on behalf of the federal government and
several states, which alleges that AstraZeneca engaged in unlawful
marketing practices in connection with its promotion of
Fasenra and Tezspire. Several other manufacturers
are also named in the complaint with respect to their promotion of
other respiratory biologics.
*
This
matter remains at an early stage.
|
|
340B State Litigation, US
Considered to be a contingent asset
|
*
AstraZeneca has
ongoing lawsuits against Arkansas, Colorado, Hawaii, Louisiana,
Maine, Maryland, Mississippi, Missouri, Nebraska, New Mexico, North
Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee,
Utah, Vermont, Washington, and West Virginia challenging the
constitutionality of each state’s 340B statute.
*
AstraZeneca has
ongoing enforcement actions in Arkansas and Louisiana for alleged
non-compliance with each state's 340B statute. In July 2026,
Louisiana issued a cease-and-desist letter concerning AstraZeneca's
340B policy.
*
In
August and September 2026, the Mississippi and Arkansas District
Courts, respectively, granted summary judgment in favor of those
states. AstraZeneca has appealed or intends to appeal those
decisions.
*
In
August 2026, courts in Colorado, Maine, and South Dakota dismissed
AstraZeneca’s complaints. AstraZeneca has
appealed.
* In
August
2026, AstraZeneca was served with an unfair trade practices
complaint by the State of Arkansas concerning its 340B
policies.
|
|
Calquence
Inflation Reduction Act Litigation,
US
Considered to be a contingent asset
|
*
In
December 2025, AstraZeneca filed a lawsuit in the US District Court
for the District of Maryland (District Court) challenging the
Center for Medicare and Medicaid Studies' interpretation of
“qualifying single source drug” under the Inflation
Reduction Act and its application in selecting Calquence for drug price
negotiation.
*
In
August 2026, the District Court entered judgment against
AstraZeneca and AstraZeneca appealed.
|
|
Tagrisso
Regulatory Proceedings, UK and
Europe
|
*
In May
2026, AstraZeneca filed separate legal actions in the UK High Court
and the General Court of the European Union challenging
determinations by the Medicines and Healthcare products Regulatory
Agency and the *
European Medicines
Agency to grant marketing authorizations for Hansoh’s
aumolertinib. No trial date has been set.
*
In
September 2026, the European Commission revoked the marketing
authorization for aumolertinib.
|
|
For the nine
months
|
World
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|||||||||
|
ended 30 September
|
|
Change
|
|
Change
|
|
Change
|
|
Change
|
|
Change
|
||||
|
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
CER %
|
|
Tagrisso
|
5,862
|
10
|
8
|
2,467
|
11
|
1,656
|
10
|
6
|
1,169
|
13
|
8
|
570
|
(3)
|
1
|
|
Imfinzi
|
5,538
|
28
|
27
|
3,128
|
26
|
627
|
35
|
33
|
1,210
|
38
|
31
|
573
|
17
|
23
|
|
Calquence
|
3,009
|
18
|
16
|
1,982
|
16
|
214
|
31
|
25
|
690
|
21
|
16
|
123
|
6
|
6
|
|
Lynparza
|
2,421
|
1
|
(2)
|
1,012
|
(4)
|
507
|
4
|
(1)
|
710
|
6
|
1
|
192
|
-
|
3
|
|
Enhertu
|
1,019
|
49
|
45
|
-
|
-
|
701
|
47
|
44
|
205
|
41
|
33
|
113
|
78
|
75
|
|
Zoladex
|
932
|
9
|
5
|
18
|
35
|
745
|
13
|
8
|
119
|
6
|
1
|
50
|
(24)
|
(26)
|
|
Truqap
|
641
|
30
|
29
|
450
|
9
|
55
|
n/m
|
n/m
|
97
|
n/m
|
n/m
|
39
|
82
|
87
|
|
Imjudo
|
263
|
4
|
4
|
157
|
(5)
|
33
|
89
|
86
|
43
|
21
|
16
|
30
|
(14)
|
(10)
|
|
Datroway
|
12
|
n/m
|
n/m
|
-
|
-
|
11
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Etcamah
|
10
|
n/m
|
n/m
|
7
|
n/m
|
3
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
Oncology
|
311
|
(3)
|
(4)
|
7
|
20
|
215
|
-
|
(3)
|
12
|
(20)
|
(21)
|
77
|
(11)
|
(5)
|
|
Oncology
|
20,018
|
16
|
14
|
9,228
|
14
|
4,767
|
19
|
15
|
4,256
|
22
|
16
|
1,767
|
6
|
10
|
|
Farxiga
|
5,602
|
(12)
|
(15)
|
795
|
(36)
|
2,200
|
(16)
|
(21)
|
2,385
|
11
|
6
|
222
|
(32)
|
(30)
|
|
Crestor
|
1,017
|
8
|
5
|
27
|
(25)
|
912
|
13
|
9
|
1
|
28
|
(14)
|
77
|
(19)
|
(16)
|
|
Lokelma
|
638
|
23
|
23
|
239
|
6
|
149
|
50
|
44
|
136
|
50
|
44
|
114
|
13
|
20
|
|
Seloken
|
518
|
11
|
6
|
-
|
n/m
|
500
|
11
|
6
|
15
|
6
|
3
|
3
|
6
|
(4)
|
|
Brilinta
|
261
|
(61)
|
(62)
|
16
|
(95)
|
207
|
2
|
(1)
|
33
|
(75)
|
(76)
|
5
|
(33)
|
(36)
|
|
Wainua
|
189
|
33
|
33
|
170
|
24
|
5
|
39
|
47
|
12
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
|
roxadustat
|
78
|
(66)
|
(67)
|
-
|
-
|
78
|
(66)
|
(67)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Baxfendy
|
12
|
n/m
|
n/m
|
11
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
CVRM
|
298
|
(29)
|
(30)
|
(11)
|
n/m
|
212
|
2
|
-
|
55
|
(54)
|
(55)
|
42
|
(11)
|
(6)
|
|
CVRM
|
8,613
|
(11)
|
(15)
|
1,247
|
(38)
|
4,264
|
(8)
|
(12)
|
2,637
|
5
|
-
|
465
|
(20)
|
(17)
|
|
Symbicort
|
2,084
|
(4)
|
(7)
|
772
|
(15)
|
653
|
5
|
1
|
425
|
5
|
(1)
|
234
|
(5)
|
(7)
|
|
Fasenra
|
1,655
|
14
|
13
|
949
|
7
|
149
|
85
|
78
|
389
|
11
|
5
|
168
|
26
|
30
|
|
Breztri
|
1,073
|
18
|
16
|
479
|
4
|
329
|
38
|
31
|
183
|
34
|
28
|
82
|
19
|
21
|
|
Tezspire
|
509
|
61
|
57
|
-
|
-
|
64
|
n/m
|
n/m
|
322
|
56
|
49
|
123
|
43
|
48
|
|
Saphnelo
|
615
|
27
|
27
|
516
|
23
|
18
|
72
|
72
|
57
|
68
|
61
|
24
|
36
|
41
|
|
Pulmicort
|
378
|
6
|
2
|
5
|
43
|
309
|
10
|
6
|
42
|
(9)
|
(14)
|
22
|
(19)
|
(19)
|
|
Airsupra
|
129
|
12
|
13
|
120
|
6
|
9
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
R&I
|
182
|
(14)
|
(16)
|
22
|
(67)
|
79
|
(17)
|
(20)
|
76
|
74
|
68
|
5
|
(6)
|
(6)
|
|
R&I
|
6,625
|
10
|
8
|
2,863
|
-
|
1,610
|
19
|
14
|
1,494
|
22
|
16
|
658
|
12
|
14
|
|
Beyfortus
|
147
|
(34)
|
(34)
|
84
|
(39)
|
-
|
-
|
-
|
61
|
(26)
|
(27)
|
2
|
(17)
|
(29)
|
|
FluMist
|
172
|
30
|
29
|
19
|
(3)
|
7
|
n/m
|
n/m
|
102
|
24
|
24
|
44
|
52
|
49
|
|
Other
ID
|
136
|
(38)
|
(41)
|
(1)
|
(38)
|
106
|
(34)
|
(38)
|
21
|
(43)
|
(48)
|
10
|
(60)
|
(57)
|
|
ID*
|
455
|
(21)
|
(22)
|
102
|
(34)
|
113
|
(30)
|
(34)
|
184
|
(9)
|
(10)
|
56
|
(1)
|
(2)
|
|
Ultomiris
|
4,016
|
16
|
16
|
2,190
|
12
|
306
|
73
|
73
|
915
|
19
|
14
|
605
|
11
|
16
|
|
Soliris
|
1,076
|
(25)
|
(26)
|
595
|
(30)
|
311
|
(5)
|
(7)
|
89
|
(44)
|
(47)
|
81
|
(24)
|
(23)
|
|
Strensiq
|
1,641
|
38
|
37
|
1,332
|
40
|
111
|
81
|
67
|
104
|
17
|
12
|
94
|
11
|
17
|
|
Koselugo
|
585
|
17
|
15
|
149
|
(5)
|
225
|
20
|
17
|
149
|
29
|
23
|
62
|
63
|
72
|
|
Other
Rare Disease
|
226
|
28
|
25
|
89
|
7
|
51
|
39
|
25
|
60
|
20
|
14
|
26
|
n/m
|
n/m
|
|
Rare Disease
|
7,544
|
12
|
11
|
4,355
|
9
|
1,004
|
27
|
24
|
1,317
|
11
|
6
|
868
|
11
|
16
|
|
Other Medicines
|
707
|
(5)
|
(6)
|
56
|
14
|
531
|
(6)
|
(8)
|
60
|
3
|
-
|
60
|
(14)
|
(12)
|
|
Total Medicines
|
43,962
|
7
|
5
|
17,851
|
4
|
12,289
|
7
|
3
|
9,948
|
15
|
9
|
3,874
|
4
|
7
|
|
For the quarter
|
World
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|||||||||
|
ended 30 September
|
|
Change
|
|
Change
|
|
Change
|
|
Change
|
|
Change
|
||||
|
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
CER %
|
|
Tagrisso
|
2,087
|
12
|
12
|
888
|
13
|
608
|
21
|
18
|
400
|
7
|
8
|
191
|
(8)
|
(1)
|
|
Imfinzi
|
1,990
|
24
|
26
|
1,120
|
23
|
229
|
36
|
35
|
429
|
25
|
27
|
212
|
19
|
29
|
|
Calquence
|
1,065
|
16
|
16
|
696
|
14
|
77
|
26
|
24
|
248
|
24
|
25
|
44
|
2
|
4
|
|
Lynparza
|
811
|
(3)
|
(3)
|
353
|
(3)
|
164
|
-
|
(2)
|
230
|
(5)
|
(4)
|
64
|
(3)
|
3
|
|
Enhertu
|
357
|
39
|
37
|
-
|
-
|
261
|
42
|
40
|
73
|
40
|
41
|
23
|
8
|
4
|
|
Zoladex
|
325
|
14
|
10
|
9
|
n/m
|
265
|
21
|
16
|
38
|
(5)
|
(5)
|
13
|
(41)
|
(42)
|
|
Truqap
|
210
|
9
|
9
|
144
|
(10)
|
20
|
n/m
|
n/m
|
32
|
83
|
85
|
14
|
56
|
66
|
|
Imjudo
|
103
|
23
|
25
|
57
|
4
|
20
|
n/m
|
n/m
|
15
|
17
|
21
|
11
|
5
|
11
|
|
Datroway
|
7
|
n/m
|
n/m
|
-
|
n/m
|
6
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Etcamah
|
7
|
n/m
|
n/m
|
7
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
Oncology
|
108
|
2
|
3
|
3
|
64
|
74
|
7
|
5
|
4
|
(17)
|
(3)
|
27
|
(10)
|
-
|
|
Oncology
|
7,070
|
15
|
15
|
3,277
|
13
|
1,724
|
25
|
22
|
1,470
|
15
|
16
|
599
|
2
|
9
|
|
Farxiga
|
1,605
|
(25)
|
(25)
|
127
|
(71)
|
582
|
(35)
|
(37)
|
799
|
14
|
16
|
97
|
(5)
|
1
|
|
Crestor
|
332
|
9
|
6
|
9
|
(25)
|
300
|
15
|
11
|
-
|
n/m
|
n/m
|
23
|
(27)
|
(23)
|
|
Lokelma
|
219
|
16
|
17
|
75
|
(8)
|
56
|
55
|
50
|
49
|
41
|
43
|
39
|
8
|
15
|
|
Seloken
|
181
|
13
|
9
|
-
|
n/m
|
174
|
14
|
9
|
6
|
3
|
2
|
1
|
6
|
3
|
|
Brilinta
|
75
|
(48)
|
(50)
|
-
|
n/m
|
65
|
(1)
|
(5)
|
9
|
(61)
|
(60)
|
1
|
(51)
|
(45)
|
|
Wainua
|
68
|
16
|
17
|
61
|
11
|
1
|
(63)
|
(32)
|
5
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
|
roxadustat
|
21
|
(73)
|
(74)
|
-
|
-
|
21
|
(73)
|
(74)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Baxfendy
|
9
|
n/m
|
n/m
|
9
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
CVRM
|
92
|
(36)
|
(34)
|
(2)
|
n/m
|
67
|
(3)
|
(4)
|
13
|
(70)
|
(68)
|
14
|
(4)
|
5
|
|
CVRM
|
2,602
|
(19)
|
(20)
|
279
|
(58)
|
1,266
|
(19)
|
(21)
|
881
|
9
|
11
|
176
|
(6)
|
-
|
|
Symbicort
|
666
|
(10)
|
(11)
|
227
|
(26)
|
236
|
5
|
2
|
129
|
(4)
|
(4)
|
74
|
(6)
|
(5)
|
|
Fasenra
|
602
|
13
|
14
|
355
|
8
|
57
|
n/m
|
95
|
131
|
7
|
8
|
59
|
18
|
25
|
|
Breztri
|
374
|
16
|
14
|
170
|
2
|
121
|
45
|
37
|
56
|
15
|
17
|
27
|
12
|
16
|
|
Tezspire
|
188
|
58
|
61
|
-
|
-
|
20
|
n/m
|
n/m
|
120
|
53
|
53
|
48
|
51
|
58
|
|
Saphnelo
|
235
|
31
|
32
|
198
|
27
|
7
|
94
|
88
|
21
|
60
|
66
|
9
|
29
|
38
|
|
Pulmicort
|
109
|
18
|
16
|
2
|
n/m
|
90
|
25
|
23
|
11
|
(9)
|
(10)
|
6
|
(32)
|
(22)
|
|
Airsupra
|
42
|
(7)
|
(4)
|
42
|
(3)
|
-
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
R&I
|
52
|
(3)
|
(3)
|
7
|
(43)
|
24
|
(2)
|
(4)
|
19
|
28
|
28
|
2
|
11
|
(12)
|
|
R&I
|
2,268
|
9
|
9
|
1,001
|
(1)
|
555
|
25
|
21
|
487
|
15
|
15
|
225
|
11
|
16
|
|
Beyfortus
|
76
|
(19)
|
(20)
|
23
|
(34)
|
-
|
-
|
-
|
52
|
(12)
|
(12)
|
1
|
-
|
-
|
|
FluMist
|
146
|
20
|
20
|
21
|
7
|
6
|
n/m
|
n/m
|
102
|
24
|
24
|
17
|
(11)
|
(7)
|
|
Other
ID
|
44
|
(24)
|
(25)
|
-
|
n/m
|
36
|
(8)
|
(12)
|
5
|
(54)
|
(52)
|
3
|
(65)
|
(55)
|
|
ID*
|
266
|
(3)
|
(3)
|
44
|
(19)
|
42
|
5
|
1
|
159
|
5
|
5
|
21
|
(24)
|
(22)
|
|
Ultomiris
|
1,432
|
17
|
19
|
792
|
15
|
116
|
82
|
86
|
310
|
14
|
16
|
214
|
7
|
15
|
|
Soliris
|
298
|
(35)
|
(35)
|
181
|
(34)
|
63
|
(38)
|
(37)
|
28
|
(40)
|
(42)
|
26
|
(29)
|
(27)
|
|
Strensiq
|
588
|
33
|
34
|
473
|
28
|
46
|
n/m
|
n/m
|
36
|
13
|
15
|
33
|
12
|
23
|
|
Koselugo
|
238
|
6
|
9
|
55
|
7
|
110
|
(2)
|
-
|
50
|
13
|
15
|
23
|
47
|
59
|
|
Other
Rare Disease
|
77
|
20
|
24
|
31
|
7
|
17
|
2
|
(1)
|
19
|
18
|
22
|
10
|
n/m
|
n/m
|
|
Rare Disease
|
2,633
|
9
|
10
|
1,532
|
8
|
352
|
15
|
17
|
443
|
8
|
9
|
306
|
8
|
16
|
|
Other Medicines
|
227
|
(2)
|
(3)
|
14
|
48
|
172
|
-
|
(1)
|
21
|
(9)
|
(13)
|
20
|
(30)
|
(24)
|
|
Total Medicines
|
15,066
|
5
|
5
|
6,147
|
2
|
4,111
|
5
|
3
|
3,461
|
12
|
13
|
1,347
|
2
|
9
|
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Enhertu
|
1,670
|
1,291
|
|
Tezspire
|
614
|
453
|
|
Beyfortus
|
279
|
252
|
|
Datroway
|
164
|
38
|
|
Other
royalty revenue
|
76
|
70
|
|
Other
Alliance Revenue
|
3
|
4
|
|
Total
|
2,806
|
2,108
|
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Farxiga: sales milestones
|
80
|
81
|
|
Crestor: sales milestones
|
32
|
-
|
|
Other
Collaboration Revenue
|
1
|
12
|
|
Total
|
113
|
93
|
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Disposal
of Zoryve interest
|
100
|
-
|
|
Other
|
518
|
281
|
|
Total
|
618
|
281
|
|
Registered office
|
UK Registrar and Transfer Office
|
Swedish Central Securities Depository
|
US Registrar and Transfer Agent
|
|
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2
0AA
|
Computershare
Investor Services PLC
The
Pavilions
Bridgwater
Road
Bristol
BS99
6ZZ
|
Euroclear
Sweden AB
PO Box
191
SE-101
23 Stockholm
|
Computershare
Investor Services
PO Box
43078
Providence
RI,
02940-3078
|
|
UK
|
UK
|
Sweden
|
US
|
|
+44 (0)
20 3749 5000
|
0800
707 1682 (UK only)
|
+46 (0)
8 402 9000
|
+1
(888) 697 8018 (US only)
|
|
|
+44 (0)
370 707 1682
|
|
+1
(781) 575 2844
|
|
|
AstraZeneca PLC
|
|
|
By: /s/ Matthew Bowden
|
|
|
Name: Matthew Bowden
|
|
|
Title: Company Secretary
|